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Abstract
Purpose: A proportion of patients with uninodular hepatocellular carcinoma (HCC) cannot benefit from potential curative
therapies such as liver transplantation, surgical resection or radiofrequency ablation. Thus, they are prone to receive transarte-
rial chemoembolization (TACE) that is a palliative option with low probability of both complete response and prolonged local
control. Herein, we assessed the combination of TACE and 3D-high dose conformal radiotherapy (3D-HDCRT) for efficacy and
safety in HCC. Methods: We retrospectively analyzed the outcome of 35 consecutive patients with uninodular HCC ≤ 100 mm,
treated by one course of TACE combined to 3D-HDCRT. The follow-up consisted on clinics, biology, hepatic CT-scan or MRI
at month-1 and -3, and thereafter every 3 months. Results: Complete response was obtained in 80% of patients following mRE-
CIST criteria (95% in HCC ≤ 50 mm, and 60% in HCC > 50 mm) with uncommon local recurrence (11%), overall survival rates
of 79%, 59% and 44% at respectively 1, 2 and 3 years (median, 37.3 months), and 11.4% grade-3/4 toxicities. Pre-therapeutic
α-fetoprotein level ≥ 200 ng/mL was found as a strong predictor of poorer outcome. Conclusion: We showed that TACE com-
bined to 3D-HDCRT can be highly efficient to reach local control and interesting overall survival rates for uninodular HCC,
with limited severe toxicities for Child-Pugh A patients. Subsequent prospective controlled trials are warranted for comparison
with therapeutic standards.
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Introduction
Hepatocellular carcinoma (HCC), one of the most common
cancer worldwide, is the main cause of mortality among
cirrhotic patients, and ranks third in terms of death by cancer.
HCC prognosis greatly varies according to tumour size and
spread as well as liver functions and general status.1,2 Except a
restrictive population of very early or early stage HCCs that
are eligible for curative options such as orthotopic liver
transplantation (OLT) or radiofrequency ablation (RFA), the
best prognosis remains with surgical resection.3 This latter
can be considered as a curative option, especially for patients
with uninodular HCC, and its feasibility is closely linked to
the tumour bulk, absence of clinically relevant portal hyper-
tension, and conserved liver functions. Tumour size is not a
limiting issue per se, but the best outcome post-surgery re-
mains for patients with HCC ≤ 5 cm. However a pattern of
concerns arises from uninodular HCCs since they might not
be eligible for curative options, and thus are candidate for
trans arterial intrahepatic chemoembolization (TACE).
TACE is a palliative option with the best reported median
overall survival around 20 months (mo). TACE induces ex-
tensive tumor necrosis in more than 50% of HCCs, but most
of tumors do not achieve a complete response (around 20%
complete responses following liver-adapted RECIST criteria),
and TACE is of limited efficacy in terms of progression-free
survival. Indeed, within or around the capsule which is sup-
plied by both arterial and portal blood, tumour cells remain
viable and are frequently responsible for subsequent progres-
sion, this consideration prompting treatment repetitions. As
the tumour response variable appears as an independent
predictive factor of survival, it seems of likelihood that com-
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plementary approaches tending to increase complete necrosis
could be of benefit on survival.4-10
Combination of three-dimensional high-dose conformal
radiotherapy (3D-HDCRT) and TACE may remedy the limi-
tation of TACE alone by adding anti-cancerous synergy, and
serving the purpose of residual cancer cell eradication after
TACE. All the so far published studies on TACE + 3D-HDCRT
combination are uncontrolled trials or retrospective analysis.
Initial studies tested norm fractionated schedules of
3D-HDCRT following TACE (25-69.3 Gy, 1.6-2 Gy/daily
fraction), leading to interesting response rates (49 to 63%),
and around 18 months overall survival. Of interest, toxicities
were reduced, including only transient elevation of liver
function tests in all patients, but without treatment-related
death.11,12 Subsequent studies compared TACE + 3D-HDCRT
combination to TACE alone in retrospective analysis, and
clearly isolated irradiation as an independent predictor of
tumour response and prolonged survival.13-15 In the present
study, we showed that, for uninodular HCC developed in
noncirrhotics or Child-Pugh A cirrhotics, the combination of
TACE and 3D-HDCRT led to high complete response rates,
low risk of local recurrence and acceptable toxicity.
Methods and Materials
Study Characteristics
In our centre, every HCC patient is mandatory reviewed by a
weekly multidisciplinary board composed of liver surgeons
and transplanters, interventional radiologists, medical on-
cologists, radiotherapists and hepatologists. Therapeutic
strategies are defined following international guidelines.7 We
retrospectively analyzed the outcome of 35 consecutive pa-
tients treated in our centre by TACE + 3D-HDCRT combina-
tion. All the patients fullfiled the following criteria: histologic
or cytologic proven and/or noninvasive imaging-based diag-
nosed HCC using AASLD criteria with CT-scan and/or mag-
netic resonance imaging (MRI) 7; solitary HCC nodule ≤ 100
mm developed within a nontransplanted liver; patient ≥ 18
years not suitable for standard curative options (OLT, surgical
resection or RFA) following international guidelines 7;
Child-Pugh A5 to B7 status if cirrhosis; absence of truncular
or lobar portal vein invasion, or suprahepatic vein invasion;
absence of previous liver irradiation; performance status < 2;
all the patients received informations on the treatment
schedule based on previously published data and freely con-
sented for this therapeutic association.
TACE Procedure
One single course of TACE was performed. All the patients
underwent baseline angiography of the celiac trunk, superior
mesenteric artery and hepatic artery using a peripheral arte-
rial approach. TACE was performed with suspension of
Doxorubicin (50 mg) and 10 ml of lipiodol, before emboliza-
tion with mixed absorbable gelatin sponge (Curaspon).
After selecting the tumor-bearing arteries, and when possible
for the most hyperselective treatment, a microcatheter was
used for the drug infusion in the segmental or supra seg-
mental arteries. Patients were discharged after recovery fol-
lowed by physical examination and blood test 3 days after
TACE. We contraindicated patients to arterial procedure
when presence of impaired clotting tests (platelet count be-
low 50 × 109/L or prothrombin activity below 50%), renal
failure, severe atheromatosis; any contraindication to doxo-
rubicin (serum bilirubin > 50 µmol/L, leucocyte count < 3 ×
109/L, cardiac ejection fraction < 50%); or endstage tumoral
disease -BCLC-D).
Radiation Therapy
3D-HDCRT radiation therapy started 10 days post-TACE 16,
including active breathing control (“respiratory gating”).17
The treatment planning computed tomography (CT) scans
were performed in the position of 3D-HDCRT. The lipiodol
tumor uptake was an effective target to define the contours of
the lesions. Nontumor and tumor volumes were outlined by
an experienced radiation oncologist from data of inspiratory
hold sequences as previously described.18 As the gating tech-
nique was used, radiation was delivered during the inspira-
tion phase. As previously reported, radiation doses were de-
termined by the dose-volume histograms (DVH) 19,20 and
normal tissue complication probabilities (NTCP).21 Total dose
was 54 Gy. However lower doses could be used - i.e. 45 or 30
Gy - depending on whether the volume of normal liver pa-
renchyma receiving 50% of the isocenter dose was respec-
tively comprised between 33% and 66%, or > 66%. Dose
constraints were included on the stomach and duodenum.
Fractionation was 3 Gy/fraction, 5 fractions/week, with
photon beam energy > 10 MeV. Clinical, biologic and radio-
logic follow-up were performed 1 month after the end of
radiotherapy, and subsequently every 3 months. The same
dosimetric schedule was equally applied for both cirrhotic
and noncirrhotic patients, taking account that all cirrhotic
patients had rather well conserved liver functions
(Child-Pugh A5 to B7). We did not use non coplanar fields
routinely. Either 2 opposed fields were used, or a technique of
5 to 8 fields was used, according to the tumor location and
tumor size. The proximity of stomach and duodenum was an
important decision tool in the choice of the fields arrange-
ment.
Assessment of Efficacy and Toxicity
Efficacy of the TACE + 3D-HDCRT combination therapy was
assessed on: tumor response by injected dynamic CT-scan (or
MRI) following liver adapted-RECIST criteria; overall sur-
vival (OS); progression-free survival (PFS); time to relapse
(TTR) for complete responders (CR), or time to progression
(TTP) for partial responders (PR) or stable diseases (SD);
safety using both the Child-Pugh score for liver toxicity, the
national cancer institute common toxicity criteria (NCI-CTC)
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version 3.0 for early toxicity (from month -1 to months -3),
and the late effects on normal tissues–subjective, objective,
management and analytic (LENTSOMA) scale for late toxicity
(from months-6 to months-12).22
Statistical Methods
Probabilities of survival were calculated from the day of
screening CT-scan (MRI) imaging according to Kaplan and
Meier.  Relationship between each of the variables and sur-
vival was assessed by log-rank test in univariate analysis.
Relationships between the different variables were analyzed
by the CHI-2 test (P value < .05 indicating significance).
Multivariate analyses were performed using Cox models for
overall survival, PFS and TTR/TTP. All statistical tests were
two-sided and p-values < .05 were considered significant.
Statistical analysis was performed using MedCalc version
12.3.0.0 software package.
Results
Between April 2005 and November 2010, 35 patients with
uninodular HCC were treated with TACE + 3D-HDCRT
combination therapy, and the medical records of these pa-
tients were retrospectively reviewed. All the patients re-
ceived both TACE and 3D-HDCRT, without any drop-out
between TACE and 3D-HDCRT due to TACE toxicity. Vari-
ables from HCC patients are summarized in Table 1. Briefly,
the mean age of patients was > 70 years, consisting mainly of
Child-Pugh A cirrhotic caucasian males. All patients had
uninodular HCC, either  50 mm for 20/35 (57%), or > 50 mm
for 15/35 (43%). Follow-up period was 23.8 ± 11.7 months
(mean ± SD). The local control rate reached 100%: 28/35
(80%) CR, 6/35 (17%) PR, and 1/35 (3%) SD (Figure 1).
TABLE 1: Patient characteristics at baseline.







54-85 (mean 72.8 ± 8.2; median 74)
28/7
34 caucasians, 1 african
29 cirrhosis / 6 noncirrhotic livers
alcohol (13), alcohol + NASH or dysmetabolic
syndrome (2), NASH or dysmetabolic syn-
drome (3), HCV (8), HCV + NASH or
dysmetabolic syndrome (2), HBV (3), hemo-
chromatisis (1), cryptogenic (3)
Tumor description
Radiological characteristics
Size of the single nodule (mm)
Adjacent neoplastic segmental portal vein thrombosis
Extrahepatic spread
Αlpha-fetoprotein (ng/mL)
Range 23-88 (mean 48.9 ± 17.1; median 50)
2
0
1-11170 (mean 480.1 ± 1910.8; median 8)
Staging system
BCLC staging classification A (28), C (7)
Liver function
Bilirubin
Aminotransferases       ASAT (N < 35 IU/L)
ALAT (N < 45 IU/L)
Albumin
Alkaline phosphatases (N < 130 IU/L)
Gamma-glutamyl transpeptidase (N < 55 IU/L)
Serum creatinine (N < 100 IU/L)
Serum sodium (N = 135-145 mEq/L)
Prothrombine time (N≥ 70%)
Platelet count (N = 150-450 Giga/L)
Child-Pugh class
A5 / A6 / B7
4-32 µM/L (mean 15 ± 7.3; median 11)
15-187 IU/L (mean 42 ± 32.9; median 27)
10-138 IU/L (mean 35 ± 27; median 29)
23.1-47.6 g/L (mean 37 ± 5.4; median 39)
69-259 IU/L (mean 123 ± 48.2; median 111)
39-683 IU/L (mean 163 ± 152.2; median 99)
69-164 µM/L (mean 94 ± 26.3; median 91)
134-146 mEq/L (mean 139 ± 2.7; median 138)
72-110% (mean 85 ± 12.2; median 81)
56-377 Giga/L (mean 159 ± 92.3; median 143)
23 / 9 / 3
General health
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FIG. 1: CT-scan image series of HCC tumor with arterial enhancement before therapy (A), Lipiodol staining but remaining arterial enhance-
ment 5 days after TACE (B), and complete devascularization 3 months after 3D-HDCRT (C).
Among the 28 CR pts, arterial contrast enhancement disap-
peared at month-1 for 17 pts (61%), at month-3 for 9 pts
(32%), and month-6 for 2 pts (7%) post-3D-HDCRT. Adja-
cent neoplastic segmental portal vein invasion (2 patients) did
not impact on the parenchymal tumor response probability,
and the portal vein invasion showed arterial uptake disap-
pearance and was devoid of progression within the portal tree
all along the follow-up. CR probability was higher for HCCs 
50 mm (19/20, 95%) vs. HCCs > 50 mm (9/15, 60%) (CHI-2,
P< .02). Pre-therapeutic -fetoprotein levels (AFP) did not
impact on CR probability: 88% for AFP ≥ 200 ng/mL vs. 78%
for AFP < 200 ng/mL; P = NS). In contrast, the absence of
normalization of AFP in CR pts with high pre-therapeutic
AFP level, was highly predictive of metastasis occurrence
(Table 2).
Median overall survival (OS) reached 37.3 months (range
5-50): 79%, 59% and 44% at respectively 1, 2 and 3 years
(Figure 2A). In multivariate analysis, pre-therapeutic AFP ≥
200 ng/mL was the best and unique significant predictive
factor of shorter overall survival (17 vs. 39 months; P = .01)
(Table 3), whereas tumor size > 50 mm and absence of CR
status were not. By the way, CR status tended to be associated
with longer OS, being aware that most non-CR were PR.
Thus they could subsequently benefit from RFA or TACE on
the tumorous residues, finally leading to CR of the target
lesion. Causes of death (n = 19) were terminal progression of
HCC (n = 8) (mean ± SD = 26 ± 12.1 months), Mendelson's
syndrome, characterized by a bronchopulmonary reaction
following aspiration of gastric contents during general an-
aesthesia, occurring a few hours post-surgical resection of
HCC recurrence (n = 1) at month-41, digestive bleeding (n =
1) at month-5, perforative umbilical hernia (n = 1) at
month-34, bacterial pneumonia (n = 1) at month-50, acute
alcoholic hepatitis (n = 1) at month-8, pancreatic adenocar-
cinoma (n = 1) at month-10, hepatorenal syndrome (n = 2) at
Before therapy
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month-17 and month-19, spontaneous bacterial peritonitis (n
= 1) at month-25, liver failure (n = 1) at month-11, and un-
known cause (n = 1) at month-11. Progression-free survival
(PFS) was 19 months in the whole population (Figure 2B). In
multivariate analysis, pre-therapeutic AFP ≥ 200 ng/mL and
albuminemia < 35 g/L were significant and independent pre-
dictive factors of shorter PFS (Table 4), respectively 11 vs. 24
months (P = .02), and 7.5 vs. 24 months (P = .02).





(N ≤ 9 ng/mL)
Post-therapeutic AFP





#1 208 6 17 Pancreatic metastasis
#2 5 4 - -
#3 74 28 7 Multifocal liver metastasis
#4 3 3 13 Multifocal liver metastasis
#5 3 3 - -
#6 8 2 19 Distant single liver nodule
#7 119 5 22 Two distant liver nodules
#8 2381 44 9 Multifocal liver metastasis + neoplastic portal
vein thrombosis
#9 6 6 6 Multifocal liver metastasis
#10 874 531 5 Bone metastasis
#11 42 3 39 Local recurrence
#12 9 9 - -
#13 3 4 -
#14 789 1470 1 Lung metastasis
#15 39 26 - -
#16 21 15 - -
#17 5 6 28 Local recurrence
#18 5 3 37 Distant single liver nodule
#19 7 8 24 Multifocal liver metastasis
#20 5 5 25 Local recurrence
#21 5 5 - -
#22 10 5 - -
#23 14 6 - -
#24 5 3 - -
#25 393 12 - -
#26 319 8 15 Lung metastasis
#27 2 2 -
#28 251 21 8 Lung metastasis
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FIG. 2: Kaplan-Meier curves for (A) overall survival probability (OS), (B) progression-free survival probabitity (PFS), and (C) recur-
rence/progression-free time probability (TTR/TTP).
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TABLE 3: Factors influencing overall survival.
Cox Proportional-Hazards Re-
gression for Univariate and Mul-
tivariate Analysis
Univariate analy-
sis HR (95% CI)
P-value Multivariate analy-




Age older than 70 years (n=24) 0.88
(0.31 - 2.53)
.82






HBV etiology (n=3) 0.00
(0.00 - 69.7E+153)
.94
HCV etiology (n=10) 1.04
(0.36 - 2.96)
.93
Alcohol etiology (n=15) 1.23
(0.48 - 3.17)
.65
Other etiology (n=7) 1.84
(0.64 - 5.31)
.25
Platelet count<150 Giga/L (n=19) 2.56
(0.91 - 7.20)
.07
Albuminemia < 35 g/L (n=8) 2.54
(0.97 - 6.66)
.05
Bilirubinemia > 20 µM/L (n=8) 2.60
(0.99 - 6.75)
.05





BCLC stage non-A (n=7) 0.87
(0.27 - 2.77)
.82
Tumor size > 50 mm (n=15) 1.53
(0.60 - 3.90)
.36
Absence of complete response




Among CR pts (n = 28), recurrences occurred in 16/28 (57%)
pts with a mean time of 20.7 ± 10.2 months (Figure 2C). Only
three of them (11%) were local recurrence inside radiation
fields. Other recurrences were either intra-hepatic outside
radiation fields (n=8) (17 ± 10.7 months) or as distant visceral
metastasis (n = 5) (7.7 ± 8.3 months). Subsequent treatments
were TACE for multifocal intra-hepatic recurrence (n = 4),
RFA for unifocal hepatic recurrence (n = 4) or surgical resec-
tion (n = 1), sorafenib for neoplastic portal vein invasion or
distant metastasis (n = 3), best supportive care for metastatic
recurrence and alteration of general status (BCLC stage D) (n
= 2). Among non-CR (n = 7), three of them could subse-
quently benefit from TACE (n = 2) or RFA (n = 1). Progres-
sion occurred in three non-CR, such as intra-hepatic pro-
gression (n = 2) (20.5 ± 7.8 months) and distant visceral me-
tastasis at month-3 (n = 1). In multivariate analysis,
pre-therapeutic AFP ≥ 200 ng/mL was highly predictive of
shorter TTR (Table 5): 8.7 vs. 25.1 months; P= .003).
Pre-therapeutic AFP ≥ 200 ng/mL was predictive of HCC
aggressiveness since present in 80% of patients who devel-
oped later occurrence of distant visceral metastasis or portal
vein invasion, vs. 17% of patients with later intra-hepatic
recurrence outside radiation fields, vs. 0% of patients with
later recurrence inside radiation fields. Median TTR tended to
associate with tumor size: 24.4 months for HCCs ≤ 50 mm vs.
15.9 months for HCCs > 50 mm (P = .0597).
Liver toxicity was assessed by the Child-Pugh score. The
pre-therapetic values (5.5 ± 0.8; n = 35 pts) significantly
worsened from month-1 (6.0 ± 1.0; t-student, P = .0184; n = 35
pts evaluable) to month-3 (6.4 ± 1.5; P= .0038; n = 35 pts
evaluable) reaching the nadir at month-6 (6.7 ± 1.6; P = .0065;
n = 33 pts evaluable due to one loss of view, and one death by
digestive bleeding). Thereafter, a slight although nonsignifi-
cant improvement occurred at month-9 (6.6 ± 1.6; P = NS; n =
30 pts evaluable due to one death by acute alcoholic hepatitis,
and two death by multifocal progression of HCC) and
month-12 (6.4 ± 1.5; P = NS; n = 27 pts evaluable due to one
death by pancreatic adenocarcinoma, one death by liver
failure, and one death of unknown cause).
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Platelet count < 150 Giga/L 2.13
(0.93 - 4.85)
.07





Bilirubinemia > 20 µM/L 2.27
(0.94 - 5.48)
.06





BCLC stage non-A 0.89
(0.33 - 2.83)
.81
Tumor size > 50 mm 1.60
(0.72 - 3.51)
.24
Absence of complete re-





No early grade-3/4 toxicities (month-1 and month-3) were
reported (Table 5). Regarding late grade-3/4 toxicities
(months 6, 9, 12), 2 pts (5.7%) developed grade-3 ascitis at
month-6, one of them cumulating grade-4 variceal bleeding.
Two additional pts developed grade-3 ascitis or gastric
bleeding at month-12, leading to a cumulative rate of 11.4%
grade-3/4 toxicities. Noticeably, only the pt developing both
grade-3 ascitis and grade-4 variceal bleeding got lethal be-
haviour that could be directly and obviously related to the
TACE + 3D-HDCRT combination therapy. Ascitis (all grades
included) was the most common side effect since occurring in
7/35 patients (20%) (Table 6).
Discussion
In the present study, we aimed to catch the antitumor effect
and safety of TACE + 3D-HDCRT combination therapy. We
focused on a specific subset of patients - i.e. those with un-
inodular HCC tumor ≤ 100 mm, ineligible for curative thera-
pies (OLT, surgical resection or RFA), and developed in
chronic liver disease (mainly cirrhosis) devoid of significant
hepatic insufficiency. We demonstrated that TACE +
3D-HDCRT can reach high rate of tumor response, interest-
ing survival rates and fairly good tolerance. Therapeutic
strategies are defined following international guidelines.7
Patients non eligible for surgery are patients with: i)
non-stage A HCC in the BCLC classification; ii) significative
portal hypertension with esophageal varices and/or por-
to-sushepatic gradient > 10 mm Hg; iii) comorbidities for-
bidding general anesthesia for surgery. Patient non eligible
for monopolar RFA were either patients with HCC tumor size
> 30 mm diameter, or patients with < 30 mm diameter HCC
with localization prohibiting percutaneous RFA (not visible
at US examination, localized in the upper the part of the liver,
in segment I, exophytic/subapsular, etc).
We chose to assess efficacy of TACE + 3D-HDCRT in un-
inodular HCCs ineligible for potential curative options.
3D-HDCRT is particularly relevant for HCCs which topog-
raphy allows radiation beams at focalizing onto a small part of
the liver and sparing the surrounding non-tumorous area.23,24
In this way, it clearly appears that uninodular HCCs are the
best candidates. In contrast, multifocal HCCs scattered in
both hepatic lobes do not seem suitable due to the potential
huge volume of irradiated non-tumorous liver parenchyma,
thus prohibiting delivering high dose of radiation by risk of
iatrogenic hepatitis. Herein, one single course of TACE was
performed followed 10 days later by 3D-HDCRT to take
Volume 2 • Number 4 • 2014                                               International Journal of Cancer Therapy and Oncology 9
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advantage of the potential synergy between ionizing radia-
tions and the cytotoxic chemotherapeutic agent (doxorubi-
cin) inside the tumor. TACE induces hypoxic necrosis, fol-
lowed by VEGF peak and regrowth of residual cancerous foci,
this event happening early post-TACE.25 Thus it seemed
important to deliver radiation therapy before re-growth of
the residual cancer cells. To this aim, we used high dosage of
photon therapy (54 Gy, 3 Gy per fraction, equivalent to 65-70
Gy total dose with 2 Gy per fraction) as compared to those
previously published: 69 Gy with 1.8 Gy per fraction, or 62
Gy with 2 Gy per fraction.11,26-28
TABLE 5: Factors influencing TTR.
Cox Proportional-Hazards
































Platelet count < 150.000/mL 1.46
(0.60 - 3.56)
.40
Albuminemia < 35 g/L 1.07
(0.30 - 3.78)
.90
Bilirubinemia > 20 µM/L 1.81
(0.65 - 5.08)
.25





BCLC stage non-A 0.38
(0.08 - 1.64)
.19
Tumor size > 50 mm 2.03
(0.81 - 5.06)
.13
Absence of complete response




TABLE 6: Adverse events within 12 months post TACE + 3D-HDCRT.
Number of adverse events Grade 1 Grade 2 Grade 3 Grade 4
Ascitis 3 1 3 0
Digestive bleeding 0 0 1 1
Hepatic encephalopathy 0 0 0 0
Hepatic pain 0 0 0 0
Post-radiation pneumopathy 1 1 0 0
Albuminemia 7 4 0 0
SGOT/SGPT 2 2 0 0
Bilirubinemia 2 4 0 0
Alkaline phosphatase 3 6 0 0
Platelet count 3 2 0 0
Prothrombin time 3 0 0 0
Creatininemia 4 2 0 0
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We showed that TACE + 3D-HDCRT combination therapy is
highly efficient for tumor destruction. Tumor size  50 mm
greatly predicted CR (95%) vs. 60% for HCCs > 50 mm, with
uncommon relapse (11%) within radiation fields for CR pts.
We previously reported that 3D-HDCRT monotherapy could
lead to 80% CR for HCCs  50 mm, but local recurrence rates
were higher (20%) than in the present TACE + 3D-HDCRT
combination (11%).18 Regarding this subset of HCCs  50 mm,
we further showed that TACE + 3D-HDRT leads to one and
3-year overall survival rates of 80% and 54% (median, 39.6
months), quite similar to those reported in literature with
percutaneous destructions or surgical resections.29 Surgical
resection was reported as treatment of choice for HCCs ≤ 50
mm, whereas OLT or RFA, these latter being more prone for
smaller HCCs (≤ 30 mm), could be alternative options in
curative intent to treat. In cohorts of subset of HCCs≤ 30 mm,
surgery is quite equivalent to RFA as illustrated by some
studies where the one and 3-year survival rates were reported
at 89% and 57% in surgical groups, and 91% and 71% in RFA
groups (P = .30). However in the same study, surgery was
more efficient than RFA for the subset of HCCs ranging from
31 to 50 mm: one and 3-year survival rates were reported at
92% and 68% in the surgical group vs. 81% and 42% in the
RFA group (P = .03).30-36Unfortunately, significant number of
patients with uninodular small size HCC cannot be treated by
these potential curative options due to patient characteristics
or tumour topography. Furthermore only a limited number of
those patients can benefit of liver transplantation. They are
thus intended to TACE that is a palliative option, giving less
than 20% complete responses, and 20 months overall surviv-
al.5 Regarding HCCs > 50 mm in the present study, TACE +
3D-HDCRT led to 64% CR, 79% and 42% overall survival
rates at one and 3-years (median, 30 months). Some published
series reported that surgical resection of HCCs > 50 mm gives
69% and 37% overall survival rates at respectively 1 and
3-years (median, 20 months) 37,38, thus at least comparable,
although with a trends to inferiority, to our TACE +
3D-HDCRT data.
In previously published studies, predictive factors of pro-
longed survival post-TACE + 3D-HDCRT were liver func-
tions as assessed by the Child-Pugh score, tumor size (< 50
mm vs. 50-100 mm vs. > 100 mm), absence of neoplastic
portal vein invasion, total dose irradiation delivered to the
tumor (60 Gy vs. 56 Gy vs. 48 Gy with 1.8 Gy/fraction).39 In
the present study, almost all patients were Child-Pugh A,
devoid of portal vein invasion and the irradiation dose was
constant (54 Gy, 3 Gy/fraction). We found pre-therapeutic
AFP < 200 ng/mL as predictive factor of prolonged survival,
and at a lesser extent since nonsignificant, tumor size ( 50
mm) and CR. Furthermore, pre-therapeutic AFP ≥ 200 ng/mL
and tumor size > 50 mm clearly appeared as predictive of
tumor recurrence such as intra-hepatic metastasis since oc-
curring mainly outside the radiation fields. Thus it's highly
possible that pre-therapeutic AFP and tumor size predict the
presence of micro metastasis spared in the liver parenchyma
before TACE + 3D-HDCRT procedure. Although tumor re-
sponse is likely a key factor for prolonged survival, this pa-
rameter did not appear as determinant in the present study
since: i) most of patients were CR and only a few were PR or
SD, thus prohibiting robust statistical comparisons; ii) all PR
pts could subsequently benefit from additional RFA or TACE
to obtain complete response on the residual living tumor
tissue within the previously irradiated nodule.
Comparing our data with those previously published in the
literature, the first study combining 3D-HDCRT (total
44-69.3 Gy, daily 1.8 Gy/fraction) and TACE was published in
1999 and enrolled patients with unresectable large size HCCs
(mean 9 ± 3.4 cm). The objective response rate was 63.3%,
and survival reached 67% and 22.2% at one and 3-years, with
17 months overall survival.11 Although achieved in uncon-
trolled settings, subsequent studies compared
TACE+3D-HDCRT to TACE monotherapy, and clearly iso-
lated irradiation as an independent positive predictor of sur-
vival. The combination therapy gave higher response rates
than TACE monotherapy (47.4% vs. 28.1%, P < .05), and
additionally prolonged survival (19 vs. 10 months, P =
.0001).13 Further studies evaluated increasing doses of radia-
tion therapy on HCC in chemo-radiation strategies (up to 60
Gy in 7.5 Gy/fraction, equivalent to 87.5 Gy in 2 Gy/fraction)
delivered by conformational hypofractionation. This radia-
tion schedule led to higher response rates (90.5%) and better
overall survival reaching 25 months.39 Regarding safety, our
data are rather encouraging since showing only 11.4% grade
3-4 toxicities, whereas previously published studies reported
huge variability in values: 13-50% grade-3 toxicities.40 The
limited high grade toxicity observed in our study may be
explained by the strict selection of patients at inclusion
(Child-Pugh A) with uninodular HCC (limiting widespread
irradiation of the liver parenchyma) and adjacent organs such
as stomach for instance.
In parallel of 3D-HDCRT, other approaches such as stereo-
tactic body radiotherapy (SBRT) reported exciting data for
inoperable HCCs. SBRT allows the delivery of higher doses of
radiotherapy as compared to 3D-HDCRT, with more accu-
racy to target the tumor volume and to spare the nontumor-
ous surrounding liver parenchyma. In Jang's et al report 41, a 3
fraction 51 Gy SBRT (range, 33-60 Gy) led to 87% local con-
trol in a dose efficient manner for tumors ranging from 10 to
70 mm, mean 31 mm, median 30 mm (100% in our study,
with tumors ranging from 23 to 88 mm, mean 49 mm, median
50 mm). The one, two and three year overall survival rates
reached 82%, 63% and 55% respectively, median around 42
months with SBRT vs. 79%, 59% and 44%, median 39.6
months in our TACE+3D-HDCRT study. Grade 3/4 toxicities
were quite similar between Jang's reports and the present
study (10% vs. 11.4%). Prospective randomized controlled
trials could compare each approach between SBRT and
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TACE+3D-HDCRT. Further the same team 42, demonstrated
that Child-Pugh A cirrhotic patients are more prone than B to
undergo SBRT since giving more > grade-2 toxicities (11.9%
for Child-Pugh A vs. 36% for B). In our study, 91% of patients
were Child-Pugh A, thus prohibiting to highlight any dif-
ferential toxicity probability between Child-Pugh A and B
patients.
Conclusion
Finally in the present study, it seems of interest to be aware
that patients with HCC of poor prognosis due to ineligibility
to surgical resection or RFA, might keep potential comparable
efficiency for tumor control and survival probability thanks
to TACE+3D-HDCRT combination therapy. However, ran-
domized controlled studies are needed to definitely clarify
this concern.  Currently, the TACERTE study is under in-
vestigation. This is a multicentre, prospective, randomized,
controlled phase 2B trial comparing TACE+3D-HDCRT vs.
TACE alone for HCCs < 10 cm and ineligible to curative
options.
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